Skip to main content
SpringerLink
Log in

Der Biomarker IDH1/2 in der Tumorpathologie

The IDH1/2 biomarker in tumor pathology

  • Molekulares Tumorboard
  • Published:
Die Pathologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Montesinos P, Recher C, Vives S, Zarcycka E, Wang J, Bertani G et al (2022) Ivosidenib and azacitidin in IDH1-mutated acute myeloid leukemia. N Engl J Med 386(16):1519–1531

    Article  CAS  PubMed  Google Scholar 

  2. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(6):796–807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pirozzi CJ, Yan H (2021) The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol 18(10):645–661

    Article  CAS  PubMed  Google Scholar 

  4. Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J et al (2023) Multicenter phase II trial of the PARP inhibitor olaparib in recurrent IDH1- and IDH2-mutant glioma. Cancer Res Commun 3(2):192–201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kerr DA, Lopez HU, Deshpande V, Hornicek FJ, Duan Z, Zhang Y et al (2013) Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. Am J Surg Pathol 37(6):787–795

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Molekularpathologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Ulrich Lehmann

  2. Institut für Pathologie, Molekularpathologisches Zentrum, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Albrecht Stenzinger

Authors
  1. Ulrich Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albrecht Stenzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Lehmann.

Ethics declarations

Interessenkonflikt

U. Lehmann und A. Stenzinger geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

U. Lehmann, Hannover

A. Stenzinger, Heidelberg

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lehmann, U., Stenzinger, A. Der Biomarker IDH1/2 in der Tumorpathologie. Pathologie 44, 318–319 (2023). https://doi.org/10.1007/s00292-023-01199-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-023-01199-0

Search

Navigation